Pfizer (NYSE:PFE) Stock Price Up 2.3% – What’s Next?

Pfizer Inc. (NYSE:PFE)’s stock price was up 2.3% during mid-day trading on Tuesday . The stock traded as high as $25.50 and last traded at $25.2450. Approximately 49,246,894 shares changed hands during trading, an increase of 17% from the average session volume of 42,244,516 shares. The stock had previously closed at $24.67.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive topline results from two Phase 3 TRANQUILLO studies of once-daily LITFULO in patients with nonsegmental vitiligo. Both the 50 mg and 100 mg doses significantly improved facial and total-body repigmentation, supporting plans for regulatory filings worldwide and providing a potential new growth opportunity beyond Pfizer’s established portfolio. Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials
• Positive Sentiment: The European Commission authorized Pfizer and BioNTech’s XFG-adapted Comirnaty COVID-19 vaccine for the 2026–2027 season in individuals six months and older. The approval allows the partners to prepare manufacturing and supply ahead of the respiratory-virus season, although commercial demand remains difficult to predict. Pfizer wins EU approval for updated COVID vaccine
• Positive Sentiment: Pfizer is advancing the Phase 2 Symbiotic-Lung-10 lung-cancer trial, adding another potential pipeline catalyst as investors look for therapies capable of offsetting declining COVID-related revenue. Pfizer’s Symbiotic-Lung-10 trial
• Neutral Sentiment: Investors are awaiting Pfizer’s second-quarter results for details on revenue trends, key-product performance, COVID-product demand, margins and full-year guidance. The company’s prior quarter exceeded estimates, but analysts remain focused on whether newer products can sustain growth.
• Negative Sentiment: The positive LITFULO and vaccine news may not immediately translate into substantial revenue: LITFULO still requires regulatory review, while seasonal COVID-19 demand is volatile. That uncertainty, combined with earnings-event risk, appears to be limiting the market’s reaction to Pfizer’s pipeline updates.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PFE shares. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Citigroup raised their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Finally, CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.50.

Pfizer Stock Down 0.9%

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market capitalization of $142.04 billion, a P/E ratio of 19.02 and a beta of 0.35. The business has a 50 day moving average price of $25.08 and a 200 day moving average price of $26.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in the company. Penn Davis Mcfarland Inc. lifted its position in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. KBC Group NV lifted its holdings in Pfizer by 8.3% during the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock worth $228,924,000 after buying an additional 706,426 shares in the last quarter. North Dakota State Investment Board bought a new position in Pfizer in the 4th quarter valued at $5,348,000. Finally, Genesis Financial Group LLC bought a new position in Pfizer in the 4th quarter valued at $961,000. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.